This is a tough call because it is unlikely that a therapy will use gene therapy to substitute LMW tau with Big tau in humans especially when there are no reliable biomarker indicating the potential for tauopathies for preventive treatment (unless the CRISPER-Cas technology becomes very accurate and efficient). This evidence concerns the gene MAPT and tauopathy.